1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
AbbVie Inc.

AbbVie Inc.

ABBV.TO
AbbVie Inc.CA flagToronto Stock Exchange
36.92
CAD
+0.09
- -
65.24BMarket Cap
AbbVie Inc.
ABBV.TO
(Toronto Stock Exchange)

Recent

price

36.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.02
1.14
1.23
1.25
1.33
1.5
1.7
1.88
2.34
2.38
2.75
3.36
3.47
3.26
3.38
3.66
3.86
Revenue per Share
0.27
0.22
0.35
0.28
0.12
0.34
0.4
0.35
0.41
0.56
0.28
0.69
0.71
0.29
0.26
0.25
0.38
Basic EPS, GAAP
0.3
0.39
0.4
0.39
0.2
0.46
0.44
0.63
0.92
0.91
1.01
1.32
1.45
1.32
1.07
1.07
1.09
Free Cash Flow per Basic Share
- -
- -
- -
0.17
0.18
0.22
0.25
0.27
0.4
0.46
0.46
0.55
0.6
0.63
0.66
0.7
0.72
Dividend per Share
9.94
7.55
2.13
2.83
1.09
2.45
2.91
3.2
-5.71
-5.53
7.41
8.71
9.75
5.87
1.88
-1.85
-3.36
Book Value per Share
3.68
1.85
-3.22
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.31
-52.55
-46.54
-43.91
-51.95
-51.79
-51.27
Tangible Book Value per Share
15,269
15,269
14,901
14,999
15,037
15,212
15,048
15,044
13,973
13,974
16,679
16,709
16,717
16,686
16,680
16,705
16,699
Basic Weighted Avg Shares
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
64,386
Sales/Revenue/Turnover
30.16
20.75
31.65
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
33.94
Operating Margin (%)
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
7,869
Depreciation Expense
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
6,310
Net Income, GAAP
13.61
6.41
7.86
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
27.39
Effective Tax Rate (%)
26.72
19.68
28.7
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
9.8
Profit Margin (%)
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-7,973
Working Capital
- -
32
14,630
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
62,481
LT Debt
15,703
11,932
3,363
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-5,888
Total Equity
52.42
24.76
34.74
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
19.15
14.04
- -
19.13
23.45
Return on Invested Capital (%)
53.21
24.8
34.63
22.79
11.66
21.78
17.49
14.53
- -
21.13
- -
14.31
15.97
8.76
- -
9.02
12.45
Return on Capital (%)
53.21
24.85
68.98
105.11
56.91
180.9
138.75
109.09
- -
- -
- -
81.04
72.48
35.22
62.52
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,555
8,326
8,341
LT Borrowings
58,941
64,532
62,481
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,768
1,767
1,767
Market Capitalization
41,711
38,803
43,647

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,062
33,529
33,669
Cash, Cash Equivalents & STI
5,257
9,391
6,569
Accounts Receivable, Net
12,589
12,479
13,824
Inventories
4,951
5,049
5,127
Total Current Liabilities
43,289
42,100
41,642
Payables & Accruals
34,734
33,774
33,301
ST Debt
8,555
8,326
8,341
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
16,990
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.08
0.09
- -
0.26
2025
0.08
0.06
0.01
0.11
0.25
2026
0.04
0.22
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.16
0.16
0.16
0.66
2025
0.18
0.17
0.17
0.17
0.7
2026
0.18
0.18
- -
- -
- -
Similar Companies
Pfizer Inc. (PFE.F)
AstraZeneca PLC (ZEG.DE)
Shangya Technology Co., Ltd. (6130.TWO)
Eli Lilly and Company (LLY)
TTK Healthcare Limited (TTKHLTCARE.NS)
Kopran Limited (KOPRAN.NS)
Business
AbbVie Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines, biologics and aesthetic products. The company operates principally through an Immunology portfolio, including Skyrizi (risankizumab) for psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis; Rinvoq (upadacitinib) for inflammatory diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease and alopecia areata; Humira (adalimumab); and other therapies for immune-mediated diseases; an Oncology portfolio comprising Imbruvica (ibrutinib), Venclexta/Venclyxto (venetoclax), Epkinly (epcoritamab), Elahere (mirvetuximab soravtansine-gynx) and other cancer medicines; a Neuroscience portfolio including Vraylar (cariprazine), Ubrelvy (ubrogepant), Qulipta (atogepant), Duodopa/Duopa (levodopa/carbidopa intestinal gel), Botox Therapeutic and Parkinson’s disease candidates; and an Eye Care portfolio featuring Restasis, Lumigan, Alphagan, Vyzulta, Vuity and related ophthalmic products. AbbVie also supplies specialty medicines in gastroenterology, dermatology, rheumatology, urology, women’s health, infectious disease and other therapeutic areas. Through its Allergan Aesthetics business, AbbVie develops and markets medical-aesthetics and consumer-facing products, including Botox Cosmetic, Juvederm dermal fillers, SkinMedica skin-care products, CoolSculpting body-contouring systems, Natrelle breast implants and related aesthetic devices and services. The company sells to wholesalers, distributors, hospitals, clinics, physicians, pharmacies, managed-care organizations and patients, with commercial operations, manufacturing facilities and research activities across the United States, Europe, Asia-Pacific, Latin America, the Middle East and Africa. AbbVie was founded in 2013 following its separation from Abbott Laboratories and is headquartered in North Chicago, Illinois, United States. Recent strategic actions include the completion in September 2026 of the approximately $10.9 billion acquisition of Apogee Therapeutics, which adds clinical-stage inflammatory and immunology candidates, including the IL-13 antibody zumilokibart for atopic dermatitis and asthma, to AbbVie’s pipeline. The company also completed the acquisition of Capstan Therapeutics, adding an in-vivo targeted lipid nanoparticle platform and an anti-CD19 CAR-T therapy candidate for B-cell-mediated autoimmune diseases, and acquired Gilgamesh Pharmaceuticals’ Phase 2 bretisilocin program for major depressive disorder. In addition, AbbVie entered into an agreement to acquire a Tempe, Arizona device-manufacturing facility and associated intellectual property from West Pharmaceutical Services to support production of current and next-generation immunology and neuroscience medicines; secured an exclusive licensing arrangement with RegeGen for a bispecific antibody targeting advanced solid tumors; and expanded manufacturing capacity through construction of a $195 million active-pharmaceutical-ingredient facility in North Chicago, expected to support immunology, oncology and neuroscience products.